#USA #Matica Bio #AAV Manufacturing #Cirsium Biosciences #College Station, Texas

Matica Biotechnology and Cirsium Biosciences Announce AAV Manufacturing Collaboration

Harnessing Innovative Technology to Advance Gene Therapy
In a significant advancement within the biotechnology sector, Matica Biotechnology, Inc. (commonly referred to as Matica Bio), renowned for its expertise in viral vector production, has entered into a transformative partnership with Cirsium Biosciences. This collaboration aims to revolutionize adeno-associated virus (AAV) technology through the implementation of groundbreaking plant-based methodologies. The announcement was officially made on September 8, 2025, highlighting the strategic intent of both companies to enhance capabilities in gene therapy manufacturing.

Matica Bio is a pioneering Contract Development and Manufacturing Organization (CDMO) specializing in creating viral vectors. Cirsium Biosciences, based in San Diego, California, focuses on developing advanced plant-based technologies to streamline AAV production. The partnership is poised to leverage Cirsium's unique hybrid hub-and-spoke manufacturing model, which integrates internal capabilities with downstream collaborators to provide increased flexibility, scalability, and distribution efficiency in the manufacturing process.

The Significance of AAV Manufacturing in Gene Therapy

The ongoing challenge for the gene therapy landscape centers around the costly and time-consuming nature of AAV production. As the demand for effective therapies grows, solutions that can enhance efficiency and reduce production timelines are critical. The strategic collaboration between Matica Bio and Cirsium seeks to address these challenges by improving manufacturing processes, ultimately making it easier to provide treatments to a broader patient population.

Paul Kim, the CEO of Matica Bio, expressed enthusiasm regarding the partnership: “Working with Cirsium aligns with our commitment to innovation in gene therapy. Their cutting-edge plant-based technology fits perfectly with our capabilities in viral vector development and clinical product manufacturing. Together, we aim to set new standards for the future of treatment availability.”

Cirsium’s solutions are designed to offer scalable infrastructures, ensuring that AAV therapy developers can navigate the complexities of manufacturing and scaling to meet clinical demands. Dr. Daniel Gibbs, who serves as CEO of Cirsium, remarked, “Our hybrid model allows us to efficiently expand AAV manufacturing capabilities. By partnering with leading entities like Matica Bio, we are committed to discovering more efficient pathways in the realm of gene therapy.”

Future Directions: Aiming for Efficiency and Accessibility

As the biotech industry continues to evolve with remarkable speed, both companies are committed to refining AAV production methods. They aspire to enable a more rapid and efficient transition from research to treatment options, which is vital for accelerating the development of gene therapies that benefit patients globally.

Matica Biotechnology prides itself on its state-of-the-art cGMP facility, equipped with the latest technological advancements to maintain quality and efficiency. With core competencies ranging from process and assay development to comprehensive cGMP manufacturing, Matica Bio positions itself as a key ally for those engaged in gene therapy initiatives. The firm utilizes proprietary innovations like MatiMax™ cell lines and in-line process monitoring to optimize operations, further enhancing the collaboration's potential to produce high-quality AAV therapies.

About the Companies

Matica Biotechnology, Inc.: Matica Bio operates as a CDMO focused on developing and producing viral vectors. Their unique offerings support efficient project workflows and high standards of quality. With a presence across several global sites, they leverage advanced technologies to cater to diverse client needs.

Cirsium Biosciences: This innovative firm utilizes cutting-edge plant-based technology to deliver high-quality viral vectors. Named after the resilient thistle plant that embodies adaptability and strength, Cirsium aims to dismantle existing barriers in AAV manufacturing, promoting accessibility to advanced therapies.

With this partnership, the future looks promising for those awaiting innovative treatments developed through the synergy of Matica Biotechnology and Cirsium Biosciences. This strategic alliance is not only a leap forward in AAV manufacturing but also a testament to the transformative power of collaboration in the biotechnology sector.